Introduction
============

Increased levels of low-density lipoprotein and total serum cholesterol are a known cause of hypercholesterolemia, mixed dyslipidemia, homozygous familial hypercholesterolemia, and coronary heart disease.[@b1-ijn-10-4059] Overall, statins are characterized by their high selectivity as HMG-CoA reductase inhibitors and do not exhibit any pertinent affinity towards other enzymes or receptor systems.[@b2-ijn-10-4059] Atorvastatin (ATR) is used to reduce levels of low-density lipoprotein, cholesterol, apolipoprotein B, and triglycerides. ATR also increases high-density lipoprotein cholesterol levels in the treatment of hyperlipidemia and dysbetalipoproteinemia (type III hyperlipoproteinemia).[@b3-ijn-10-4059] ATR has a unique crystalline structure, undergoes hepatic first-pass metabolism, and has very good intestinal permeability and better low-density lipoprotein-lowering potency compared with other HMG-CoA reductase inhibitors.[@b4-ijn-10-4059]

ATR belongs to Biopharmaceutics Classification System class II, showing low oral bioavailability (12%) due to low aqueous solubility (0.1 mg/mL), high presystemic clearance in the gastrointestinal mucosa (\>80%), and extensive hepatic first-pass metabolism.[@b5-ijn-10-4059] The poor performance of ATR means that higher doses of the drug need to be administered, which may lead to liver abnormalities, myopathy, rhabdomyolysis, arthralgia, and kidney failure.[@b6-ijn-10-4059]--[@b8-ijn-10-4059]

Interest in developing novel oral delivery vehicles to improve the bioavailability of lipophilic drugs is growing worldwide.[@b9-ijn-10-4059],[@b10-ijn-10-4059] Nanoparticulate formulations depend on the choice of suitable formulation components having maximum encapsulation efficiency (EE) and improvement of bioavailability and retention time.[@b11-ijn-10-4059] Like other nanoparticle formulations, the key factor in improving the oral performance of drugs when incorporated into nanoparticles is a reduction in particle size. The decrease in particle size results in an increase in surface area and solubility, which in turn improves the release rate of the drug and provides high concentrations in the gastrointestinal tract.[@b12-ijn-10-4059],[@b13-ijn-10-4059]

The zein polymer is composed of a group of alcohol-soluble proteins that are present predominantly in the endosperm of corn kernels.[@b13-ijn-10-4059] As a drug delivery vehicle, zein shows good biocompatibility and does not induce an autoimmune response or celiac disease.[@b14-ijn-10-4059] Nanoparticulate formulations utilizing zein have shown improved absorbability and less toxicity than synthetic polymeric nanoparticulate formulations.[@b7-ijn-10-4059],[@b15-ijn-10-4059]--[@b17-ijn-10-4059] It can also overcome the drawbacks of a hydrophilic polymeric system in order to achieve sustained drug release.[@b12-ijn-10-4059]

The aim of this study was to enhance the dissolution rate and modify the release characteristics of ATR, a poorly water-soluble drug, via creation of zein nanospheres. Development of this formulation involved size reduction to the nanoscale and utilization of optimization to understand the experimental parameters affecting the formulation in order to enhance the oral delivery and bioavailability of ATR. An in vivo study using adult Wistar albino rats was done to investigate the pharmacokinetic parameters of the developed zein nanospheres in comparison with the commercial product.

Materials and methods
=====================

Materials
---------

ATR (≥98%, CAS number 134523-03-8) was kindly supplied by the Egyptian International Pharmaceutical Industry Company (10th of Ramadan City, Egypt). Zein (≥97%, CAS number 9010-66-6), ethanol, methanol, and all other chemicals were obtained from Sigma-Aldrich (St Louis, MO, USA).

Mathematical experimental design and formulation of ATR--zein nanospheres
-------------------------------------------------------------------------

Fractional factorial design was custom-constructed in this study using statistical package JMP 7.1 software (SAS Institute, Cary, NC, USA). According to the preliminary results, all process parameters were investigated and the most significant parameters were specified (data not shown). The factors studied were weight % of zein to ATR (X~1~), pH value (X~2~), and stirring time (X~3~). Levels for each formulation variable were designed. The selected dependent variables were mean particle size (Y~1~), zeta potential (Y~2~), drug loading efficiency (Y~3~), drug encapsulation efficiency (Y~4~), and yield percentage (Y~5~). The factor levels of design are presented in [Table 1](#t1-ijn-10-4059){ref-type="table"}. Twelve experimental runs of ATR--zein nanosphere formulations were prepared by a liquid--liquid phase separation method, as shown in [Table 1](#t1-ijn-10-4059){ref-type="table"}. Each run was carried out in triplicate. Twenty-five milligrams of ATR and the corresponding weight of zein were dissolved completely in 10 mL of 80% ethanol utilizing a probe sonicator (VCX 750, Sonics & Materials Inc, Newtown, CT, USA). The obtained ethanol solution was immersed in 18 mL of deionized water. The resulting dispersion was stirred at 2,000 rpm at room temperature for 3 hours until evaporation of the ethanol. The dispersion was subjected to centrifugation at 20,000 rpm followed by freeze-drying for 72 hours using mannitol as a cryoprotectant. The mannitol concentration was added as a 1:1 weight ratio to the amount of polymer used. Mannitol was removed by exhaustive dialysis prior to drug analysis.

Characterization of the prepared ATR--zein nanospheres
------------------------------------------------------

### Particle size and zeta potential

The number weighed particle size of the freshly prepared nanospheres was determined by a laser diffraction technique. The particle size and zeta potential were measured using a Zetatrac analyzer (Microtrac Inc, Montgomeryville, PA, USA).

### Drug loading efficiency, encapsulation efficiency, and yield

A specific weight of the lyophilized powder of ATR--zein nanospheres was dissolved in 100 mL of methanol using a probe sonicator and subjected to high-performance liquid chromatography analysis (Agilent 1200 series, equipped with an ultraviolet diode array detector, and an automatic sampling system, Agilent Technologies, Santa Barbara, CA, USA). Drug loading efficiency, EE, and percent yield were determined by [equations 1](#fd1-ijn-10-4059){ref-type="disp-formula"}, [2](#fd2-ijn-10-4059){ref-type="disp-formula"}, and [3](#fd3-ijn-10-4059){ref-type="disp-formula"}, respectively.[@b18-ijn-10-4059],[@b19-ijn-10-4059] $$\text{Drug~loading~efficiency}(\% w/w) = \left( \frac{\text{ATR~mass~in~nanospheres}}{\text{Mass~of~nanosphere}} \right) \times 100$$ $$\text{Drug~encapsulation~efficiency}(\% w/w) = \left( \frac{\text{ATR~mass~in~nanospheres}}{\text{Mass~of~feed~drug}} \right) \times 100$$ $$\text{Yield}(\% w/w) = \left( \frac{\text{Mass~of~collected~dry~nanospheres}}{\text{Total~mass~of~formulation~components}} \right) \times 100$$

### Morphology of ATR--zein nanospheres

The surface morphology of the prepared ATR nanospheres was visualized with a scanning electron microscope (JEM-100 CX, JEOL, Tokyo, Japan). Before observation, the samples were fixed onto metal aluminum stubs using double-sided sticky tape and then coated with gold under vacuum.

### Powder X-ray diffraction assay

The crystalline state of ATR in the optimized formulation was confirmed using a powder X-ray diffractometer (D/max 2500, Rigaku, Tokyo, Japan) with CuKα radiation. The obtained data were typically collected between 3° and 45°. Diffraction patterns were recorded for 20 minutes.

### In vitro diffusion study

Diffusion of ATR from the prepared nanospheres was carried out using automated Franz diffusion cell apparatus (MicroettePlus, Hanson Research, Chatsworth, CA, USA) with a 1.76 cm^2^ diffusion area and a receptor chamber volume of 7 mL. A synthetic nylon membrane with a 0.45 μm pore size (Pall Corporation, Port Washington, NY, USA) was used as the diffusion membrane. The developed nanospheres were placed between the donor and receptor compartments. The temperature was maintained at 37°C±0.5°C. Phosphate-buffered saline (pH 7.0, 0.01 M) was used as a diffusion medium in the receptor chamber and stirred at 400 rpm. Aliquots were withdrawn at 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours by the autosampler and analyzed for ATR content using a validated high-performance liquid chromatography technique.[@b20-ijn-10-4059] Each test was carried out in triplicate.

Pharmacokinetic study of optimized ATR--zein nanospheres
--------------------------------------------------------

Adult female Wistar albino rats weighing 200--250 g were used for the in vivo experiments. Animal use was approved by the local institutional review board for preclinical and clinical research that ensures the care and use of animals conforms to the European Union Directive 2010/63/EU on the protection of animals used for scientific purposes.

The animals were divided into four groups, containing six rats each. The first group received orally administered plain zein nanospheres (negative control). The second group received an orally administered ATR suspension at a dose of 25 mg/kg body weight (positive control).[@b21-ijn-10-4059],[@b22-ijn-10-4059] The third group received an orally administered optimized formulation of ATR--zein nanospheres at the same dose. The fourth group received an orally administered suspension of commercial tablets at the same dose. All groups were administered the oral formulations using a ball-tipped feeding needle. Blood samples (0.25 mL) were withdrawn from the tail vein at 0 (pre-dose), 0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 hours into microcentrifuge tubes. Plasma levels of ATR were determined using a validated high-performance liquid chromatography method.[@b23-ijn-10-4059] Pharmacokinetic parameters, ie, maximum plasma concentration (C~max~), time point of maximum plasma concentration, elimination rate constant (K~e~), half-life, mean residence time, and area under the plasma concentration-time curve (AUC) were calculated based on serum ATR concentrations. Pharmacokinetic parameters were calculated by noncompartmental methods using Kinetica software for pharmacokinetic/pharmacodynamic data analysis version 4.2 (Thermo Scientific Corporation, Philadelphia, PA, USA).

Results and discussion
======================

Mathematical experimental design and formulation of ATR--zein nanospheres
-------------------------------------------------------------------------

This study aimed to develop ATR--zein nanospheres to obtain the optimum formulation and control preparation factors. According to custom fractional factorial design, the factor combinations yielded various values of observed mean dependent variables. The results for Y~1~ were in the range of 183--1,540 nm for runs 5 and 11, respectively ([Table 2](#t2-ijn-10-4059){ref-type="table"}). The zeta potential (Y~2~) showed a highest value of 18.2 (run 2) and the lowest value, ie, closest to zero, was -1.1 (run 10). It has been reported that zein is positively charged, and the variation in zeta potential values could be attributed to adsorption of the ionized salt of the drug in the alkaline hydration medium at the surface of the zein nanospheres.[@b24-ijn-10-4059] The highest value for Y~3~ and Y~4~ was achieved by run 2, while run 5 showed the highest value for Y~5~ ([Table 2](#t2-ijn-10-4059){ref-type="table"}).

Analysis of variance results for the investigated dependent variables (Y~1~--Y~5~) are shown in [Table 3](#t3-ijn-10-4059){ref-type="table"}. Evidence of a regression effect is considered for a *P*-value of 0.05 or less.

Accordingly, a significant effect of the independent factors on the dependent variables Y~1~, Y~2~, Y~3~ and Y~5~ was indicated, with *P*-values of 0.028, 0.0062, 0.0145, and 0.0057, respectively. The estimated effects and associated *P*-values for the investigated dependent variables were 0.048, 0.0015, and 0.0043 for the dependent variables Y~1~, Y~2~, and Y~5~, respectively ([Table 4](#t4-ijn-10-4059){ref-type="table"}). These results indicate significant effects of the interaction term X~2~.X~3~ on the dependent variables Y~1~, Y~2~, and Y~5~, as shown in [Table 4](#t4-ijn-10-4059){ref-type="table"}. The *P*-values for Y3 showed significant effects of 0.047, 0.0466, and 0.043 for the independent factors X~1~ and X~3~ and the interaction term X~1~X~2~, respectively. Three-dimensional response surface plots for the estimated dependent variables were constructed according to the polynomial functions to assess the change of the response surface ([Figure 1](#f1-ijn-10-4059){ref-type="fig"}). Since the model has more than two factors, two factors were held constant for each diagram; therefore, a total of five response surface plots were produced.

Linear correlations of the quantile--quantile relationships were produced from plotting the measured parameters against the predicted ones ([Figure 2](#f2-ijn-10-4059){ref-type="fig"}). The relationships showed *r*^2^ values of 0.89, 0.94, 0.92, 0.73, and 0.94 for Y~1~, Y~2~, Y~3~, Y~4~, and Y~5~ respectively. These values indicate the validity of the corresponding models for predicting the investigated dependent variables within the predesigned design spaces ([Figure 2](#f2-ijn-10-4059){ref-type="fig"}). Pareto charts were used to rank the independent variables including their interaction terms according to magnitude of their influences on the dependent variables ([Figure 3](#f3-ijn-10-4059){ref-type="fig"}). The chart includes a vertical reference line at the critical *P*-value of 0.05. An effect that exceeds the vertical line is considered to be statistically significant. On the other hand, positive signs of the factors' estimates illustrate direct relationships of the studied factors with the dependent variables. On the other hand, negative signs show inverse relationships.

The results showed that increasing the weight % of zein to ATR (X~1~) increases the mean particle size and loading efficiency significantly. The drug EE is significantly affected by pH in a direct proportional profile. This can be explained by the unfolding of the protein molecule of zein at basic pH, which increases the thiol--disulfide interchange reaction, and may enhance drug inclusion and particle formation, but inhibits formation of large aggregates.[@b12-ijn-10-4059] In addition, improved loading and EE by the increase in weight % of zein to ATR could be attributed to the enhanced partitioning of ATR to the hydrophobic matrix of zein. The significant effect of X~3~ and the interaction term X~1~X~3~ influencing the surface charge intensity of the prepared ATR-zein nanospheres could be attributed to variation in adsorption of the ionized form of the drug in the medium at the surface of the zein nanospheres with variation in X~3~ ([Figure 3](#f3-ijn-10-4059){ref-type="fig"}). The yield was significantly increased by increased stirring time, which enhanced the homogeneous distribution of the antisolvent droplets, dispersing ATR in the formed zein nanospheres. The reduced model prediction equations ([equations 4](#fd4-ijn-10-4059){ref-type="disp-formula"}--[8](#fd8-ijn-10-4059){ref-type="disp-formula"}) including the individual effects of the independent variables and their interaction terms were generated using mathematical regression models for the observed dependent variables, Y~1~, Y~2~, Y~3~, Y~4~, and Y~5~. Theoretical values of the dependent variables were obtained by substitution of the X~1~--X~3~ values in these equations. $$\begin{array}{l}
{Y_{1} = 5.42 \times 10^{8} - 3.96 \times 10^{8} \times \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack} \\
{\mspace{22mu} + 1.81 \times 10^{8} \times \left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5. \times 10^{3}} \right\rbrack} \\
{\mspace{22mu} + 4.45 \times 10^{8} \times \left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack + \left\lbrack \frac{X_{1} - 0.55}{0.45} \right\rbrack} \\
{\mspace{22mu} \times \left\lbrack {\left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack \times - 1.34 \times 10^{4}} \right\rbrack} \\
{\mspace{22mu} + \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack \times \left\lbrack {\left\lbrack \frac{X_{3} - 165}{135} \right\rbrack \times 4.95 \times 10^{2}} \right\rbrack} \\
{\mspace{22mu} + \left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack \times \left\lbrack {\left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack \times 1.48 \times 10^{8}} \right\rbrack} \\
\end{array}$$ $$\begin{array}{l}
{Y_{2} = 2.43 \times 10^{6} - 5.1 \times 10^{2} \times \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack} \\
{\mspace{22mu} + 8.14 \times 10^{5} \times \left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack + 1.98} \\
{\mspace{22mu} \times 10^{6} \times \left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack + \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack} \\
{\mspace{22mu} \times \left\lbrack {\left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack \times - 1.83 \times 10^{2}} \right\rbrack} \\
{\mspace{22mu} + \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack \times \left\lbrack {\left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack \times 3.17 \times 10^{1}} \right\rbrack} \\
{\mspace{22mu} + \left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack \times \left\lbrack {\left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack \times 6.63 \times 10^{5}} \right\rbrack} \\
\end{array}$$ $$\begin{array}{l}
{Y_{3} = - 2.67 \times 10^{7} - 2.92 \times 10^{3} \times \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack} \\
{\mspace{22mu} - 8.91 \times 10^{6} \times \left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack} \\
{\mspace{22mu} - 2.27 \times 10^{7} \times \left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack + \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack} \\
{\mspace{22mu} \times \left\lbrack {\left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack \times - 9.75 \times 10^{2}} \right\rbrack} \\
{\mspace{22mu} + \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack \times \left\lbrack {\left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack \times 5.30} \right\rbrack} \\
{\mspace{22mu} + \left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack} \\
{\mspace{22mu} \times \left\lbrack {\left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack \times - 7.56 \times 10^{6}} \right\rbrack} \\
\end{array}$$ $$\begin{array}{l}
{Y_{4} = - 6.62 \times 10^{7} - 9.99 \times 10^{3} \times \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack} \\
{\mspace{22mu} - 2.21 \times 10^{7} \times \left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack} \\
{\mspace{22mu} - 5.66 \times 10^{7} \times \left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack + \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack} \\
{\mspace{22mu} \times \left\lbrack {\left\lbrack \frac{{(X}_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack \times - 3.33 \times 10^{3}} \right\rbrack} \\
{\mspace{22mu} + \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack \times \left\lbrack {\left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack \times - 0.78} \right\rbrack} \\
{\mspace{22mu} + \left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack \times \left\lbrack {\left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack \times - 1.89 \times 10^{7}} \right\rbrack} \\
\end{array}$$ $$\begin{array}{l}
{Y_{5} = 9.58 \times 10^{6} - 4.01 \times 10^{3} \times \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack} \\
{\mspace{22mu} + 3.19 \times 10^{6} \times \left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack} \\
{\mspace{22mu} + 7.29 \times 10^{6} \times \left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack + \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack} \\
{\mspace{22mu} \times \left\lbrack {\left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack \times - 1.33 \times 10^{3}} \right\rbrack + \left\lbrack \frac{(X_{1} - 0.55)}{0.45} \right\rbrack} \\
{\mspace{22mu} \times \left\lbrack {\left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack \times - 2.82 \times 10^{1}} \right\rbrack} \\
{\mspace{22mu} + \left\lbrack \frac{(X_{2} - 1.5 \times 10^{4})}{5 \times 10^{3}} \right\rbrack \times \left\lbrack {\left\lbrack \frac{(X_{3} - 165)}{135} \right\rbrack \times 2.43 \times 10^{6}} \right\rbrack} \\
\end{array}$$

Drug-nanoparticulate delivery systems show particular promise for high payloads, extended circulation times, and active targeting capabilities. Nanoparticulate systems help to realize the potential of new therapeutic entities, improve the delivery of currently used drugs, increase the maximum tolerated dose, and improve dissolution rates and bioavailability.[@b25-ijn-10-4059]--[@b28-ijn-10-4059] Therefore, there is a pressing need to develop general techniques for the formulation of therapeutic nanoparticles.[@b29-ijn-10-4059]--[@b32-ijn-10-4059] Zein nanospheres, with size range of 150--550 nm, can be produced from ethanolic solution using antisolvent procedures with water as an antisolvent. The particle size for the 12 formulae ranged from 183 nm to 1,540 nm. The coagulation and adherence of zein nanospheres may be the reason for the high values of some formulae due to a high proportion of zein in these formulae in comparison with ATR. This conclusion is in agreement with previous reports.[@b12-ijn-10-4059],[@b33-ijn-10-4059] The increase in particle size could be attributed to the smaller amount of ATR found on the nanosphere surface, which could lead to an increase in interfacial tension between the particle surface and the aqueous medium, and hence an increased particle diameter.

After analyzing the effect of the independent variables (X~1~--X~3~) on the dependent variables (Y~1~--Y~5~), the levels of these factors were specified using a computer optimization process and a desirability function. Accordingly, the predicted values of Y~1~, Y~2~, Y~3~, Y~4~, and Y~5~ were 186.3 nm, −11.92 mV, 14.79%, 29.71%, and 93.1%, respectively. These predicted values were deduced at X~1~, X~2~, and X~3~ levels of 85%, 8.8%, and 1.4%, respectively. To confirm the output predictions, a fresh formulation of ATR--zein nanospheres was prepared with the specified predicted values, ie, optimized weight % of zein to ATR (85%), pH 8.8, and a stirring time of 1.4 hours. These optimized levels yielded a formulation with a particle size of 191 nm, a zeta potential of −12.7 mV, a drug loading efficiency of 15.64%, an EE of 28.99%, and a yield of 93.6%. The close agreement of the observed and predicted values demonstrated the reliability of the optimization procedure in predicting the characteristics of the ATR--zein nanosphere formulation. The 191 nm particle size of the optimized formula would not be possibly recognized by the reticuloendothelial system to allow long residence time of the nanospheres in the body. In addition, if the formula was applied as a parenteral dosage form, it would be suitable for sterilization by filtration.

The scanning electron microscopic image of the optimized ATR--zein nanosphere formula is shown in [Figure 4](#f4-ijn-10-4059){ref-type="fig"}. The nanospheres showed spherical morphology, with smooth surfaces that have no cracks or pores. The diameter of the particles was consistent with the particle size measured by the laser diffraction technique.

X-ray diffraction analysis was also performed to inspect the physical state of ATR in the developed formula after the formulation process. The raw ATR showed intense crystalline peaks between 5° and 45°C. Zein nanospheres loaded with ATR exhibited broad peaks that indicate transformation of a great extent of drug crystallinity to the amorphous form ([Figure 5](#f5-ijn-10-4059){ref-type="fig"}). Transformation of ATR to an amorphous form, with its high-energy and highly disordered state, would result in an enhanced dissolution rate and improved bioavailability.[@b18-ijn-10-4059]

[Figure 6](#f6-ijn-10-4059){ref-type="fig"} shows the percentage of ATR diffused from the optimized ATR--zein nanospheres. The results show a biphasic sustained-release pattern during the 48-hour release study. The initial release is usually attributed to rapid release of drug entrapped near the surface of the nanospheres. This is mainly related to the heterogeneous drug distribution. Drug particles either loosely associated with the surface or embedded in the surface layer are responsible for the burst release. A low polymer concentration also results in high internal porosity and high initial bursts.[@b19-ijn-10-4059]--[@b22-ijn-10-4059] After the initial stage, release of ATR was characterized by a period of slow release. After 12 hours, about 41.76% of the ATR in the zein nanospheres was released. About 53.1% of the entrapped ATR was released after 24 hours ([Figure 6](#f6-ijn-10-4059){ref-type="fig"}). The slow pattern of ATR release from the nanospheres after the initial stage could be attributed to the ATR that is more deeply entrapped in the core matrix of the zein nanospheres. ATR in the core of the nanospheres has a longer diffusion path to reach the surface compared with ATR entrapped near the surface.[@b11-ijn-10-4059] The release of ATR from the core matrix of the zein nanospheres is controlled by parameters that affect the kinetics of drug release from a polymeric matrix. In addition, the hydrophobic nature of zein augments the delay of water penetration and could slow down the diffusion of the poorly water-soluble ATR into the dissolution medium.

Pharmacokinetic study of optimized ATR--zein nanospheres
--------------------------------------------------------

The pharmacokinetic study showed lower initial plasma concentrations relative to the oral suspension and commercial ATR tablets for the first 3 hours. There was a high burst release for the ATR--zein formulation. This action continued until reaching C~max~ in less than 4 hours, followed by a sharp decrease in plasma levels. This can be attributed to some extent of ATR adhesion to the nanospheres surface that suggest the need for efficient washing procedures for the prepared nanospheres. Optimized ATR--zein showed a higher C~max~ and a relative higher area under the plasma concentration-time curve compared with the ATR suspension and commercial tablets, as shown in [Figure 7](#f7-ijn-10-4059){ref-type="fig"}. The C~max~ for ATR was 1,788.99, 8,650.32, and 1,780.82 ng/mL for the ATR suspension, optimized ATR--zein nanospheres, and commercial tablets, respectively ([Figure 7](#f7-ijn-10-4059){ref-type="fig"}, inset table). Our results also showed that zein nanospheres could significantly modify the pharmacokinetic profile and increase the bioavailability of ATR by more than 3-fold in comparison with the oral suspension and the commercially available tablets.

These results indicate that formulation of ATR as zein nanospheres enhanced its dissolution and absorption across the wall of the gastrointestinal tract. This could be attributed to the fact that preparation of ATR in the form of nanospheres enhances not only solubility of ATR, but also tissue permeability and paracellular absorption of the prepared nanospheres in the gastrointestinal tract. Further, the nanospheres introduce the formulated drug as a fine dispersion rather than the coarse particles of oral suspension, hence an increased surface area with a reduced diffusion path length.[@b7-ijn-10-4059] These results demonstrate the promising features of zein nanospheres, which enhance the oral delivery and bioavailability of ATR in vivo.

Conclusion
==========

Development of optimized ATR--zein nanospheres can improve the pharmacokinetic profile and bioavailability of ATR by more than 3-fold in comparison with ATR oral suspension. We conclude that formulation of zein nanospheres loaded with ATR enhanced the bioavailability and sustained the release of ATR. Further in vitro--in vivo correlation studies are in progress to identify the optimum dosage regimen with the least toxicity.
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![Three-dimensional response surface plots showing the effect of the study factors on the dependent variables.](ijn-10-4059Fig1){#f1-ijn-10-4059}

![Quantile--quantile plots for predicting the dependent variables.\
**Abbreviations:** RMSE, root-mean-square error.](ijn-10-4059Fig2){#f2-ijn-10-4059}

![Standard Pareto charts showing the effects of independent variables and their combined effects on mean particle size, zeta potential, drug loading efficiency, drug encapsulation efficiency, and yield.](ijn-10-4059Fig3){#f3-ijn-10-4059}

![Scanning electron micrograph of optimized atorvastatin--zein formulation.](ijn-10-4059Fig4){#f4-ijn-10-4059}

![X-ray diffraction patterns of raw atorvastatin and optimized atorvastatin-- zein nanospheres.\
**Abbreviation:** ATR, atorvastatin.](ijn-10-4059Fig5){#f5-ijn-10-4059}

![In vitro diffusion of optimized atorvastatin--zein nanospheres.\
**Abbreviation:** ATR, atorvastatin.](ijn-10-4059Fig6){#f6-ijn-10-4059}

![Means of plasma concentration-time profiles and in vivo pharmacokinetic parameters (inset) for optimized atorvastatin--zein nanospheres versus atorvastatin suspension and the commercially available tablets after a 25 mg/kg oral dose of atorvastatin.\
**Abbreviations:** AUC, area under the concentration time curve; ATR, atorvastatin; MRT, mean residence time.](ijn-10-4059Fig7){#f7-ijn-10-4059}

###### 

Experimental runs showing combinations of factors

  Run   Factors          
  ----- --------- ------ -----
  1     50        8.75   1.5
  2     50        9.25   1.5
  3     50        8.75   3
  4     50        9.25   3
  5     83.3      8.75   1.5
  6     83.3      9.25   1.5
  7     83.3      8.75   3
  8     83.3      9.25   3
  9     90.1      8.75   1.5
  10    90.1      9.25   1.5
  11    90.1      8.75   3
  12    90.1      9.25   3

**Notes:** X~1~, weight % of zein to atorvastatin; X~2~, pH; X~3~, stirring time (hours).

###### 

Observed responses for 12 formulations of experimental design

  Run number   Responses                            
  ------------ ----------- -------- ------- ------- ------
  1            378         17.79    15      7.5     40
  2            412         18.2     33.67   67.34   52
  3            316         −13.82   17.22   34.44   76
  4            395         −14.5    19.72   39.44   88
  5            483         −1.92    14.86   29.71   64
  6            223         −8.3     17.7    43.33   61.3
  7            830         −7.39    12.8    17.6    66.6
  8            877         −9.13    12.1    24.14   68.7
  9            722         −2.34    9.04    18.08   62.4
  10           619         −2.1     14.8    19.5    62
  11           1,045       −3.4     12.52   25.04   72.4
  12           1,089       −4.5     12.72   25.44   75.3

**Abbreviations:** Y~1~, mean particle size (nm); Y~2~, zeta potential (mV); Y~3~, drug loading efficiency (%); Y~4~, drug encapsulation efficiency (%); Y~5~, yield (%).

###### 

Analysis of variance of multiple regression analysis for the investigated dependent variables

  Response model   ANOVA for dependent variables Y~1~--Y~5~                                    
  ---------------- ------------------------------------------ ------------ --------- --------- --------
  Y~1~             6                                          825,316.23   137,553   6.6047    0.0280
  Y~2~             6                                          1,146.5905   191.098   13.1972   0.0062
  Y~3~             6                                          394.61791    65.7697   8.9970    0.0145
  Y~4~             6                                          1,935.4322   322.572   2.2046    0.2017
  Y~5~             6                                          1,550.8723   258.479   13.6949   0.0057

**Notes:** Y~1~, mean particle size (nm); Y~2~, zeta potential (mV); Y~3~, drug loading efficiency (%); Y~4~, drug encapsulation efficiency (%); Y~5~, yield (%).

**Abbreviation:** ANOVA, analysis of variance; df, degrees of freedom.

###### 

Estimated effects and associated *P*-values for all five dependent variables

  Dependent variables   Factor                                                                                                                                                                                                                                         
  --------------------- --------------------------------------------------- ------------- ---------------------------------------------------- ---------------------------------------------------- ------------- ---------------------------------------------------- -----------
  Y~1~                  Estimated effect                                    542,497,837   −39,595.45                                           180,963,768                                          445,176,611   −13,406.9                                            494.72416
  *P*-value             0.3630                                              0.5589        0.3629                                               0.3676                                               0.5532        0.0480[\*](#tfn5-ijn-10-4059){ref-type="table-fn"}   
  Y~2~                  Estimated effect                                    2,432,924.9   −509.9535                                            814,005.24                                           1,981,473.2   −182.7979                                            31.673902
  *P*-value             0.8715                                              0.7722        0.8711                                               0.8738                                               0.7558        0.0015[\*](#tfn5-ijn-10-4059){ref-type="table-fn"}   
  Y~3~                  Estimated effect                                    26,709,931    −2,918.294                                           −8,908,207                                           −22,676,528   −975.4479                                            5.3025948
  *P*-value             0.047[\*](#tfn5-ijn-10-4059){ref-type="table-fn"}   0.057         0.0466[\*](#tfn5-ijn-10-4059){ref-type="table-fn"}   0.0432[\*](#tfn5-ijn-10-4059){ref-type="table-fn"}   0.0567        0.1964                                               
  Y~4~                  Estimated effect                                    66,168,786    −9,987.112                                           −22,069,457                                          −56,612,169   −3,330.671                                           −0.782373
  *P*-value             0.2052                                              0.1184        0.2052                                               0.1934                                               0.1184        0.9627                                               
  Y~5~                  Estimated effect                                    9,576,282.7   −4,013.15                                            3,191,485.5                                          7,291,855.7   −1,327.189                                           −28.2089
  *P*-value             0.5829                                              0.0890        0.5832                                               0.6132                                               0.0910        0.0043[\*](#tfn5-ijn-10-4059){ref-type="table-fn"}   

**Notes:**

Significant effect of factors on individual dependent variables. Y~1~, mean particle size (nm); Y~2~, zeta potential (mV); Y~3~, drug loading efficiency (%); Y~4~, drug encapsulation efficiency (%); Y~5~, yield (%); X~1~, weight % of zein to atorvastatin; X~2~, pH; X~3~, stirring time (hours).
